ArticleJournal of biosciences2020
DNA replication and sister chromatid cohesion 1 promotes breast carcinoma progression by modulating the Wnt/β-catenin signaling and p53 protein.
Article in Journal of biosciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 14 citations in OpenAlex.
- Prognostic Significance of DSCC1, a Biomarker Associated with Aggressive Features of Breast Cancer.Medicina (Kaunas, Lithuania) · 2024Article
- Complementary biomarkers of computed tomography for diagnostic grading of gastric cancer: DSCC1 and GINS1.Aging · 2024Article
- Decoding the DSCC1 gene as a pan-cancer biomarker in human cancers via comprehensive multi-omics analyses.American journal of translational research · 2024Article
- Transcription Factor E2F4 Promote Proliferation, Migration, and Invasion of Gastric Cancer Cells by transcriptionally activating DSCC1.International journal of biological sciences · 2024Article
- DSCC1 interacts with HSP90AB1 and promotes the progression of lung adenocarcinoma via regulating ER stress.Cancer cell international · 2023Article
- In silico recognition of a prognostic signature in basal-like breast cancer patients.PloS one · 2022Article
- High DSCC1 Level Predicts Poor Prognosis of Lung Adenocarcinoma.International journal of general medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of this study is to assess the prognostic and functional role of DSCC1 in breast carcinoma, as well as the potential mechanism. Based upon the TCGA data, the expression pattern and prognostic value of DSCC1 in breast carcinoma was evaluated. The mRNA and protein levels of molecules were determined using qRT-PCR and Western blot. In vitro functional role of DSCC1 in tumor cells was determined using cell counting kit 8, clone formation, and Transwell assays. Gene set enrichment analysis (GSEA) was conducted to determine DSCC1 related gene sets, which are further confirmed by Western blot. The results showed that DSCC1 is overexpressed in breast carcinoma tissues and its high expression was linked to shorter overall survival. Overexpression of DSCC1 facilitated the proliferation, invasion and migration of breast carcinoma cells, while knockdown of DSCC1 showed opposite outcomes. GSEA showed that high DSCC1 expression had a positive correlation with p53, and Wnt signaling-related molecules. Western blot showed that silencing DSCC1 increased the levels of p53 and p-β-catenin, whereas decreased p-GSK-3β and cyclin D1 expression. These observations illustrate that DSCC1 emerges a well value on the diagnosis and prognosis of breast carcinoma, and facilitates the progression of breast carcinoma partly by activating Wnt/b-catenin signaling and inhibiting p53.
Indexed as
Identifiers
33184243W3093088836What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.